-
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830 ·
Phase: Phase 2 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female)
· Washington: Kirkland, Spokane
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643 ·
Phase: Phase 2 ·
Ages: 45 Years to 75 Years ·
Sex: All (male and female)
· Washington: Kirkland
-
A Study of Buntanetap in Participants With PD
NCT07284784 ·
Phase: Phase 2, Phase 3 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female)
· Washington: Spokane
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400 ·
Phase: Phase 1 ·
Ages: 30 Years to 85 Years ·
Sex: All (male and female)
· Washington: Kirkland, Spokane
-
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268 ·
Phase: Phase 2, Phase 3 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female)
· Washington: Bellevue, Seattle
-
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT07432958 ·
Phase: Phase 2 ·
Ages: 30 Years to 80 Years ·
Sex: All (male and female)
· Washington: Kirkland
-
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
NCT07804615 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Washington: Kirkland, Spokane
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522 ·
Phase: Phase 3 ·
Ages: 45 Years to 75 Years ·
Sex: All (male and female)
· Washington: Kirkland
-
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
NCT07330258 ·
Phase: Not specified ·
Ages: 45 Years to 75 Years ·
Sex: All (male and female)
· Washington: Seattle
-
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
NCT07005180 ·
Phase: Phase 2 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female)
· Washington: Spokane
-
Modifiable Variables in Parkinsonism (MVP)
NCT02194816 ·
Phase: Not specified ·
Ages: 19 Years and older ·
Sex: All (male and female)
· Washington: Kenmore
-
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785 ·
Phase: Not specified ·
Ages: 30 Years and older ·
Sex: All (male and female)
· Washington: Seattle
-
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Washington: Kirkland, Spokane
-
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
NCT04373317 ·
Phase: Phase 4 ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Washington: Seattle
-
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Washington: Kirkland, Seattle, Spokane
-
The GBA Multimodal Study in Parkinson's Disease
NCT04101968 ·
Phase: Not specified ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Washington: Seattle
-
The Parkinson's Genetic Research Study
NCT01558479 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Washington: Seattle
-
Use of CereGate Therapy for Freezing of Gait in PD
NCT05292794 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years to 80 Years ·
Sex: All (male and female)
· Washington: Seattle